Mar 19, 2012
Date: Friday 23th March, 2012
Time: Presentation 5pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)
Title: To List, or Not To List, That is the Question
Presented by David Blake, co-founder and co-editor of Bioshares.
Listing on the stock exchange is one of the key options for companies wanting financial security. But how to know when an IPO will be successful – and how to get to that point? Guest speaker David Blake, co-founder and co-editor of Bioshares will speak about the imperative for companies to have a well developed capital career plan from their inception if they are to maximise the probability of their success. Such an approach impacts on all aspects of the company; their business strategy, product development and management composition.
During his presentation, David will analyse the pathway to success for two listed Australian companies – Acrux (a drug delivery company that completed a $300M license deal) and Mesoblast (a $2B company based on adult stem cells).
Many of you will be familiar with Bioshares as Australia’s leading biotech stock report, delivering independent investment research to investors on ASX listed biotech, pharmaceutical and healthcare companies. It also organises a highly regarded Biotechnology summit each year designed to inform the investment sector and to encourage investment in the life science industry. Last year Bioshares had support from NZTE to hold this summit in New Zealand (Queenstown), attracting many international investors. The summit will be held in Queenstown again this year.
Please join us to discuss with David the mind set and practices he believes biocompanies need to adopt to maximise financial and investment success.
All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email email@example.com or phone (09) 373 7599 ext 89625 or 0274 305 758.